Formation of the tRNALys packaging complex in HIV-1

Lawrence Kleimana,*, Christopher P. Jonesb, Karin Musier-Forsythb,*

aLady Davis Institute for Medical Research, McGill AIDS Centre, Jewish General Hospital, 3755 Cote St. Catherine Rd., Montreal, Quebec, Canada H3T1E2
bDepartments of Chemistry and Biochemistry, Center for Retroviral Research, and Center for RNA Biology, The Ohio State University, 100 West 18th Avenue, Columbus, OH 43210, United States

A R T I C L E   I N F O

Article history:
Received 19 October 2009
Revised 4 November 2009
Accepted 10 November 2009
Available online 13 November 2009

Edited by Manuel Santos

Keywords:
tRNA packaging
HIV-1 assembly
Capsid
Gag
Gag-Pol
Lysyl-tRNA synthetase

A B S T R A C T

Human immunodeficiency virus 1 (HIV-1) uses a host cell tRNALys3 molecule to prime reverse transcription of the viral RNA genome into double-stranded RT DNA prior to integration into the host genome. All three human tRNALys isoacceptors along with human lysyl-tRNA synthetase (LysRS) are selectively packaged into HIV-1. Packaging of LysRS requires the viral Gag polyprotein and incorporation of tRNALys additionally requires the Gag-Pol precursor. A model that incorporates the known interactions between components of the putative packaging complex is presented. The molecular interactions that direct assembly of the tRNALys/LysRS packaging complex hold promise for the development of new anti-viral agents.

1. Introduction

During the replication of human immunodeficiency virus 1 (HIV-1), the viral RNA genome is converted into double-stranded proviral DNA during reverse transcription. Initiation of reverse transcription is primed by a cellular tRNA, tRNALys3, which is selectively incorporated into the virus during its assembly. Fig. 1A shows the components of HIV-1. The virus particle is surrounded by membrane derived from the cell plasma membrane (PM) during viral budding. Proteins comprising the viral structure include the glycosylated envelope proteins and mature structural proteins resulting from the proteolytic processing of the Gag precursor protein: matrix (MA), underlying the membrane; capsid (CA), comprising the wall of the core, within which are two strands of viral RNA genome; and nucleocapsid (NC), binding to the viral RNA.

Additionally, three virally-encoded enzymes used during the HIV-1 lifecycle are protease (PR), reverse transcriptase (RT), and integrase (IN). PR and IN (not shown in Fig. 1A) form homodimers or homotetramers while RT is a heterodimer. They are created upon processing of the Gag-Pol precursor protein by viral PR.

The replication cycle of HIV-1 is shown in Fig. 1B (for review, see [1]). Briefly, HIV-1 envelope proteins bind to PM receptors of the target cell, resulting in fusion of viral and cell membranes. Upon its release into the cytoplasm, the CA core disassembles, and within the resulting nucleoprotein complex, the viral RNA genome is copied into a double-stranded cDNA by RT. The tRNA primer, which is annealed to the genomic RNA primer binding site (PBS), initiates reverse transcription [2], a complex process involving multiple strand-transfer reactions facilitated by the NC protein, a nucleic acid chaperone [3]. The resultant double-stranded viral DNA within the pre-integration complex is translocated into the nucleus of the infected cell where it integrates into the host cell’s DNA and codes for viral mRNA and proteins. Envelope protein and regulatory proteins are coded for by spliced mRNAs, while both Gag and Gag-Pol are translated from full-length viral RNA, which is packaged into assembling virions where it serves as viral genomic RNA.

The Gag and Gag-Pol proteins assemble at the PM, and during or immediately after budding from the cell, the viral PR is activated and cleaves the precursor proteins into the mature products shown in Fig. 1A. A number of host cell factors are packaged during the
viral assembly step, including the tRNA\textsuperscript{Lys} primer. Transfer RNAs are known to participate in a channeled life cycle in mammalian cells, and are virtually never free [4]. For this reason, the primer tRNA cannot be selected from the microenvironment and must be present in the mature CA core prior to initiation of reverse transcription, which may initiate prior to capsid disassembly [5,6]. Thus, during virus assembly, viral genomic RNA and cellular tRNA\textsuperscript{Lys} isoacceptors (tRNA\textsuperscript{Lys,3} and tRNA\textsuperscript{Lys,1,2}) are selectively concentrated at the site of assembly. A portion of the incorporated tRNA\textsuperscript{Lys} is annealed near the 5′ end of the viral RNA to the 18-nucleotide PBS sequence, which is perfectly complementary to the 3′-18 nucleotides of tRNA\textsuperscript{Lys,3}. It is not known whether tRNA annealing occurs prior to, or after, viral budding.

In lentiviruses, including HIV-1, tRNA\textsuperscript{Lys,3} serves as the primer tRNA [7]. However, in avian retroviruses, tRNA\textsuperscript{Trp} is the primer for all members of the avian sarcoma and leukosis virus group examined to date [8,9], whereas tRNA\textsuperscript{Pro} is the common primer for murine leukemia virus (MuLV) [10]. "Selective packaging of tRNA" refers to the increase in the percentage of the low molecular weight RNA population representing primer tRNA in going from the cytoplasm to the virus. For example, in avian myeloblastosis virus (AMV), the relative concentration of tRNA\textsuperscript{Trp} changes from 1.4% to 32% [9]. In HIV-1 produced from COS7 cells transfected with HIV-1 proviral DNA, both primer tRNA\textsuperscript{Lys,3} and the other major tRNA\textsuperscript{Lys} isoacceptors, tRNA\textsuperscript{Lys,1} and tRNA\textsuperscript{Lys,2}, are selectively packaged. The relative concentration of tRNA\textsuperscript{Lys} changes from 5–6% in the cytoplasm to 50-60% in the virus [11]. tRNA\textsuperscript{Lys,1,2}, which differs from tRNA\textsuperscript{Lys,3} by 14 or 16 bases, represents two tRNA\textsuperscript{Lys} isoacceptors differing by 1 bp in the anticodon stem. While not involved in functioning as a primer in HIV-1, evidence has been found suggesting that tRNA\textsuperscript{Lys,1,2} may play a role in the import of the pre-integration complex into the nucleus of the infected cell [12]. In MuLV, selective packaging of primer tRNA\textsuperscript{Pro} is less dramatic, going from a relative cytoplasmic concentration of 5–6% to 12–24% of low molecular weight RNA [9]. The selective concentration of tRNA\textsuperscript{Pro} is required for optimizing both annealing and infec-
tivity of the HIV-1 population [13], and an understanding of this process requires an understanding of how viral RNA, tRNA^{lys}, and viral and cellular proteins interact during HIV-1 assembly.

2. Gag/Gag-Pol assembly

Gag alone is capable of forming extracellular Gag viral-like particles (VLPs), but this assembly requires RNA for its formation, and in the absence of genomic RNA, cellular RNA can perform this function [14–17]. It is generally assumed that Gag forms multimolecular complexes at cell membranes (PM or endosomal [18]), but a pre-membrane formation of smaller Gag complexes containing genomic RNA has not been excluded. Genomic RNA is packaged through interactions between NC protein sequences in Gag with specific stem/loop structures at the 5' end of the genomic RNA [19,20]. A potential role for MA, another nucleic acid binding domain, has also been proposed [21,22]. The in vivo interaction of Gag with Gag-Pol has also been well documented [23,24], and it is believed that Gag-Pol is carried into the assembling particle by interaction with CA and spacer peptide-1 (SP1) domains of Gag [25]. Cryoelectron microscopy has indicated that in immature virions, Gag is radially distributed with the N-terminal sequences within the MA domain associated with membrane, and the C-terminal sequences coding for SP1–NC-spacer peptide 2 (SP2)–p6 domains nearest the center of the virion [26,27]. Images of immature virions have suggested that Gag molecules may be arranged in interacting hexagonal bundles, with a Gag molecule at each vertex of the hexagon [28–31], a model supported by work studying the in vitro assembly of Gag [32]. The hexagonal order, however, appears to be primarily at the level of CA and SP1, and the N- or C-terminal regions of Gag are largely dispersed [28–31], supporting the conclusion that Gag/Gag interactions occur primarily at the CA/SP1 region.

3. tRNA^{lys} incorporation into HIV-1

Selective tRNA^{lys} packaging into HIV-1 occurs independent of the genomic RNA [11]. Gag-Pol is required for packaging tRNA^{lys} into Gag VLPs or into HIV-1 [11], and more specifically, the thumb (TH) structural domain in RT plays an important role in the interaction between Gag-Pol and tRNA^{lys} [33]. Although Gag-Pol appears to play a role in stable incorporation of tRNA^{lys}, it is believed that Gag is responsible for selecting tRNA^{lys} isoacceptors for incorporation into VLPs. This selection is not direct but is mediated through specific interactions with the Gag-Pol tRNA^{lys} binding protein, human lysyl-tRNA synthetase (LysRS) [34–37]. LysRS is responsible for binding and aminoacylating all three tRNA^{lys} isoacceptors that are found in HIV-1 particles [38]. Gag alone is sufficient for incorporation of LysRS into Gag VLPs [38], but as mentioned earlier, Gag-Pol is required for tRNA^{lys} incorporation as well [11]. Moreover, the packaging of tRNA^{lys} isoacceptors requires interaction with LysRS [39] but not aminoacylation of the tRNA [40].

The interaction of Gag with LysRS is specific, i.e., of nine aminoacyl-tRNA synthetases (aaRSs) and three related proteins tested, only LysRS is packaged into HIV-1 [41]. The domains critical for the interaction have been mapped to include the so-called motif 1 domain of LysRS and the C-terminal domain of CA [34]. Deletions that extend into either of these domains abolish the interaction in vitro and, importantly, eliminate packaging of LysRS into Gag VLPs [34]. Interestingly, both of these primarily helical regions are responsible for homodimerization of their respective proteins. An equilibrium binding constant of 310 nM was measured for the Gag/LysRS interaction in vitro, and CA alone binds to LysRS with a similar affinity (∼400 nM) as full-length Gag [35,36]. Mutant Gag and LysRS that do not homodimerize still interact, suggesting that dimerization of each protein per se is not required for the interaction, even though amino acids proximal to regions involved in forming the homodimer interfaces contribute to heterodimer formation. Gel chromatography studies further support the formation of a Gag/LysRS heterodimer in vitro. It is not known, however, if Gag interacts in vivo with the monomeric, dimeric, or tetrameric state of LysRS [42].

Newly-synthesized LysRS is the source of viral LysRS, which likely interacts with Gag before entering its identified steady-state cellular compartments (high molecular weight multisynthetase complex (MSC), nuclei, mitochondria, cell membrane) [41,43]. Importantly, siRNA knockdown of newly synthesized LysRS (80%) results in similarly reduced levels of tRNA^{lys} packaging, tRNA^{lys,3} priming by reverse transcriptase, and viral infectivity [43]. It has also been reported that mitochondrial LysRS (mLysRS) is a source of viral LysRS [37,44]. In human cells, cytoplasmic LysRS (cLysRS) and mLysRS are encoded from the same gene by means of alternate splicing. The two LysRS species share 576 identical amino acids, but mLysRS has a different N-terminus of 49 amino acids that contains a putative mitochondrial targeting sequence [45]. In HIV-1 produced from U937 cells, antibodies directed to full-length LysRS detected full-length and truncated species, while antibodies specific for the unique N-termini of cLysRS and mLysRS were only able to detect mLysRS. These data support the conclusion that mLysRS is a source of viral LysRS [37]. However, the conclusion that mLysRS is the sole source of viral LysRS contradicts several reports in which expression of exogenous cLysRS in transduced HIV-1 producing cells results in cLysRS incorporation [13,34,40,46]. This enhancement in LysRS packaging is associated with increases in tRNA^{lys} packaging, tRNA^{lys,3} annealing, and viral infectivity [13]. We suggest that the inability to detect cLysRS in virions using antibodies directed to the N-terminus may be associated with the lability of the N-terminus of cLysRS [38]. In vitro mapping studies also support the possibility that both forms of LysRS are possible sources for viral packaged LysRS, as the region of interaction with Gag is the motif 1 dimer interface present in both mitochondrial and cytoplasmic forms of the synthetase [35,36].

4. Formation of the tRNA^{lys} packaging complex

While tRNA^{lys} is targeted for incorporation into HIV-1 by a specific interaction of HIV-1 Gag with LysRS, RT sequences within Gag-Pol must also be present, or LysRS will be packaged without tRNA^{lys} [33,38]. Predicted relationships within the putative tRNA^{lys} packaging complex are schematically shown in Fig. 2, along with the mature protein sequences coded for by the Gag and Gag-Pol precursors. In Fig. 2, a Gag/Gag-Pol/viral RNA complex interacts with a tRNA^{lys,3}/LysRS complex, with Gag binding specifically to LysRS, and tRNA^{lys,3} binding to RT domain in Gag-Pol. In the virus, tRNA^{lys,3} is uncharged (i.e., has a free 3' hydroxyl group on the ribose of the terminal adenosine) [47], and must be in this state in order to act as a primer for RT. It is not known if tRNA^{lys,3} is uncharged at the time of these interactions, or if the interaction of Gag with LysRS facilitates deacylation and release of tRNA^{lys} from the synthetase. In vitro studies have shown that the presence of Gag inhibits aminoacylation by human LysRS but does not promote deacylation of Lys-tRNA^{lys} (R. Kennedy, M. Hong, and K. Musier-Forsyth, unpublished data).

Based on the following data, we predict that the Gag/Gag-Pol ratio in the tRNA^{lys} packaging complex is lower than the ratio present in the budding virion. When transfected 293T cells producing HIV-1 are pulsed for 10 min with ^35^S-Cys/Met, ~15% of newly-synthesized Gag and >95% of newly-synthesized Gag-Pol are found associated with membrane domains enriched in lipid rafts [48], a
membrane microdomain from which HIV-1 is proposed to bud [49,50]. The Gag and Gag-Pol molecules at this membrane domain are presumably interacting since the movement of Gag-Pol to membrane requires association with Gag, which is driven by the interaction between homologous Gag sequences within Gag and Gag-Pol [23,51]. Since the ratio of synthesis of Gag/Gag-Pol in cells has been estimated to be approximately 20:1 [52], the ratio of newly-synthesized Gag/Gag-Pol at lipid raft domains would be 3:1—much lower than the Gag:Gag-Pol ratio found in immature virions. It was observed that during a 30-min chase period, more Gag molecules moved towards lipid raft-enriched membrane [48], implying that the tRNA Lys,3 packaging/annealing complex may represent a very early assembly intermediate to which more Gag is later added. However, this assembly intermediate has not been directly detected.

In such an assembly intermediate, Gag-Pol may be present as a dimer, which is required for later Gag and Gag-Pol processing [53]. Gag and Gag-Pol would be present in a 3:1 ratio. LysRS may be present as a monomer since monomeric LysRS has been shown to interact with monomeric Gag in vitro [36]. However, as mentioned earlier the oligomeric state of LysRS upon interaction with Gag in vivo is not known. Gag-Pol may adopt a conformation to interact with Gag, reminiscent of the intermolecular interaction between Pol and Gag in human foamy viruses [54]. Expression of HIV-1 Pol and Gag from separate plasmids in 293T cells results in the incorporation of Pol into Gag VLPs, and Pol can replace Gag-Pol in facilitating the selective incorporation of tRNA Lys,3 into the Gag VLPs [55]. Recent reports also indicate that RT sequences alone can be incorporated into Gag VLPs, with apparent interactions occurring between MA and p6 sequences in Gag and the TH domain in RT [56,57].

The association of Gag-Pol with Gag is most likely driven by an interaction between homologous Gag sequences in both molecules, and the model in Fig. 2 shows the additional interactions that have been proposed to date. The model shows tRNA Lys,3 bound to TH in RT, which is based both on in vitro studies on the interaction of purified HIV-1 RT with tRNA Lys,3 [58,59], and in vivo studies on the effect of C-terminal deletions in Gag-Pol upon tRNA Lys,3 incorporation into HIV-1 [33,60]. The model also shows the 5′ region of viral genomic RNA. HIV-1 genomic RNA is packaged into the virus through interactions between NC sequences in Gag and specific stem/loop structures at the 5′ end of the genomic RNA [19,20]. The PBS is located within 100 nucleotides upstream of these sequences. Additional interactions between LysRS and genomic RNA proximal to the PBS may also facilitate tRNA targeting and placement (C. Jones, J. Saadatmand, L. Kleiman, and K. Musier-Forsyth, unpublished data). During viral maturation, the first PR cleavage is between SP1 and NCP7 [61]. An interaction between Pol and Gag could insure that Pol is retained in the partially closed budding particle if proteolytic cleavage initiates during assembly. The fact that p6 is required for the interaction of Gag with Pol is of interest since it has been reported that the deletion of p6 from Gag resulted in a lower concentration of Pol products in PR-positive HIV-1, but no change in Gag-Pol incorporation in PR-negative viruses [62].

The model in Fig. 2 suggests that an interaction between LysRS and Pol sequences might facilitate formation of the complex. In support of this model, an interaction between LysRS and the connection domain (CD)/RNaseH domains in RT has been reported [57]. LysRS and mature RT do not interact in vitro (T. Stello, L. Kleiman, and K. Musier-Forsyth, unpublished data), and thus, this interaction may only occur in the context of Pol or may be indirect, and the function of this interaction is not yet clear. Since C-terminal deletions of Gag-Pol that include the RT CD do not inhibit tRNA Lys,3 packaging [60], the LysRS/RT interaction is not involved in facilitating tRNA Lys,3 packaging. On the other hand, virions in which Gag-Pol is C-terminally deleted through the RT CD do not contain annealed tRNA Lys,3. This could mean that a Gag/LysRS/RT interaction may be involved in conformational changes facilitating movement of tRNA Lys,3 towards the PBS.

In summary, based on the current estimates of ~2500 Gag molecules in immature HIV-1 particles [31,63,64], we estimate that within the tRNA Lys,3 packaging complex, an early assembly intermediate, there may be approximately 300 molecules of Gag, 100 molecules of Gag-Pol, 25 molecules of LysRS [65], and 20–25 molecules of tRNA Lys [47] in addition to viral genomic RNA. Our model in
Fig. 2 indicates that Gag-Pol, LysRS and tRNA\[^{\text{Lys,3}}\] should be proximal to the Gag molecule(s) that are chaperoning tRNA annealing (see below), in order to facilitate transfer of tRNA\[^{\text{Lys,3}}\] from LysRS to the PBS, via RT. Ongoing studies are aimed at understanding whether additional interactions between LysRS and genomic RNA help to target this complex to the PBS region.

5. When does annealing of tRNA\[^{\text{Lys,3}}\] to viral RNA occur?

Previous in vitro studies have shown HIV-1 NC to be a very effective nucleic acid chaperone protein that facilitates nucleic acid remodeling events throughout the reverse transcription process [66]. Although NC can efficiently catalyze tRNA\[^{\text{Lys,3}}\] annealing onto the PBS in vitro [67], in viruses lacking active PR, tRNA annealing to the PBS still occurs, suggesting that the precursor protein Gag may act as a NA chaperone and facilitate this process in vivo [68,69]. Indeed, Gag\[^{\Delta p6}\], which lacks the C-terminal p6 domain, and other assembly-competent Gag variants have been demonstrated to facilitate tRNA annealing and genome dimerization in vitro [70,71]. New studies also show that Gag’s chaperone activity is stimulated upon interacting with inositol phosphates in the PM (C. Jones, S. Datta, A. Rein, I. Rouzina, and K. Musier-Forys, submitted).

While it has been demonstrated that the selective packaging of primer tRNA\[^{\text{Lys,3}}\] into HIV-1 is correlated with achieving optimal annealing of tRNA\[^{\text{Lys,3}}\] and infectivity of the HIV-1 population [13], it is not known whether selective packaging of tRNA\[^{\text{Lys,3}}\] is required for annealing. That is, selective packaging of tRNA\[^{\text{Lys,3}}\] into the virus may be due to a higher local concentration of tRNA at the site of viral assembly, where annealing may take place prior to viral budding. It has been shown that tRNA\[^{\text{Lys,3}}\] annealed in vivo or in vitro to viral RNA by Gag has a reduced ability to initiate reverse transcription [72] and results in a less stably annealed state relative to tRNA\[^{\text{Lys,3}}\] annealed by NC [69]. This reduced ability of Gag-annealed tRNA\[^{\text{Lys,3}}\] to function as a primer for reverse transcription can be rescued by a transient exposure of total viral RNA isolated from PR-negative virions to NC. Taken together, these data suggest that tRNA\[^{\text{Lys,3}}\] annealing may be a two-step process, involving an initial Gag-facilitated annealing at the site of viral assembly, followed by a re-annealing by NC after protein processing. Alternatively, NC may chaperone the refolding of viral RNA into an alternative structure to the one stabilized by Gag. Evidence for an RNA structural change that could govern RT initiation has been described [73].

6. Future prospects

Understanding the mechanism by which the tRNA packaging complex is targeted to the 5’ region of the genomic RNA, and probing the timing of tRNA annealing in the viral lifecycle are just two of the open questions currently under investigation. Gag interacts with viral genomic RNA and the PM, but Gag’s interactions with other host cell factors such as LysRS, ABC1E, cyclophilin A, Tsg101, and ALIX are also critical to virus infectivity [38,74–77]. Interaction with so many cellular factors may be achieved by distinct pools of Gag, each interacting with separate essential factors and ultimately mixing during assembly at the PM. How newly synthesized LysRS is diverted from its normal function in translation and ultimately mixing during assembly at the PM. How newly synthesized LysRS is diverted from its normal role in translation to aid virus replication. aarSS have been shown to function in a wide array of cellular processes that are distinct from aminoclylation [78]. The expanded functions of synthetases and other components of the MSC have been shown to be regulated at the level of posttranslational modification. For example, in the case of human glutamyl-prolyl tRNA synthetase (EPRS), phosphorylation is required for its release from the MSC and for formation of the heterotetrmeric \(\gamma\)-interferon-activated inhibitor of translation (GAI) complex [79–81]. Recently, specific phosphorylation of human LysRS has been shown to regulate ApA production in response to immunological challenge [82]. Phosphorylation results in release of LysRS from the MSC, enhanced ApA synthesis, and transcriptional activation via interaction with MITF [82]. While we do not yet know the phosphorylation state of LysRS that is incorporated into HIV, one intriguing possibility is that HIV infection triggers posttranslational modifications that modulate the oligomerization state of LysRS and/or LysRS–protein interactions.

References

simian virus 40 late replacement vector are efficiently processed and assembled into virus-like particles. J. Virol. 64, 2743–2750.


